Three large clinical trials have consistently shown that SGLT‐2 inhibition on top of standard of care (RAS inhibition) significantly reduces the risk of progression of CKD in people with type 2 diabetes and CKD.10 This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.